Nuclear Medicine is where advanced science meets precision healthcare.

By using safe, trace amounts of radioactive materials—called radiotracers—this cutting-edge technology allows doctors to see what’s happening inside the body at the molecular level, long before structural changes become visible through conventional imaging.

Unlike standard scans that show anatomy, Nuclear Medicine reveals function — helping detect disease earlier, guide personalized treatment, and monitor therapy effectiveness with unmatched accuracy.

From endocrinology and cardiology to neurology and oncology, nuclear medicine is transforming diagnosis, patient's management and therapeutic care across multiple specialties.

At KAX radiopharmaceutical consulting,  we offer expert clinical insight to support deep understanding of the dynamic environment of innovative radio pharmaceuticals, along with the more traditional imaging!

Radioligand Therapies (RLTs) represent a groundbreaking advance in cancer treatment, combining the precision of molecular targeting with the power of radiation therapy. Each RLT consists of a targeting molecule (ligand) linked to a therapeutic radioisotope, designed to seek out and destroy cancer cells wherever they exist in the body.

Cancer cells often display unique markers on their surface—features not found on healthy cells. RLTs exploit this difference: the ligand binds specifically to these cancer cell markers, delivering radiation directly and selectively to malignant tissues while sparing surrounding healthy organs.

Today, RLTs are clinically established treatments for neuroendocrine neoplasms (NENs) and metastatic castration-resistant prostate cancer (mCRPC). Over the past two decades, they have become an integral part of cancer care, officially included in international treatment guidelines as second- or third-line options.

RLTs belong to the broader field of radiotheranostics—a fusion of diagnostics and therapy that also includes radionuclide therapy, radioimmunotherapy, and selective internal radiation therapy (SIRT).

These therapies are transforming the outlook for many cancer patients. They can reduce pain, prolong survival, and significantly improve quality of life (QoL). In advanced prostate cancer, RLTs have already demonstrated meaningful benefits—offering effective treatment with limited side effects and a renewed sense of hope.

Since Lutathera® (lutetium Lu-177 DOTATATE) approvals in Europe in 2017 and the U.S. in 2018,  it has been administered to more than 9,000 gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients in Europe and the United States.”  Novartis stated in 2021.

Pluvicto® (lutetium Lu-177 vipivotide tetraxetan) represents a major advance in targeted radioligand therapy for prostate cancer.

Approved by the FDA in 2022, Pluvicto®  is indicated for the treatment of adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).

In March 2025, the FDA expanded its indication to include patients previously treated with an androgen-receptor pathway inhibitor (ARPI) who are eligible to delay taxane-based chemotherapy—broadening access to this innovative, precision-guided therapy for even more men living with advanced prostate cancer.

For more information on our capabilities, please contact us.